X4 Pharmaceuticals Inc
XFOR5.335USD
+5.145+2707.89%
Close 04/28, 16:00（ET）Quotes delayed by 15 min
912.00MMarket Cap
LossP/E TTM
More Details of X4 Pharmaceuticals Inc Company
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
Company codeXFOR
Company nameX4 Pharmaceuticals Inc
IPO dateNov 16, 2017
Founded at2010
CEODr. Paula Ragan, Ph.D.
Number of employees143
Security typeOrdinary Share
Fiscal year-endNov 16
Address61 North Beacon Street
CityBOSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02134
Phone18575298300
Websitehttps://www.x4pharma.com/
Company codeXFOR
IPO dateNov 16, 2017
Founded at2010
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Mr. David W.J. Mcgirr
Mr. David W.J. Mcgirr
Independent Director
Independent Director
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholder
Update time: Sun, Feb 23
Update time: Sun, Feb 23
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
Shareholder Statistics
Shareholder
Proportion
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
Type
Shareholder
Proportion
Investment Advisor
25.05%
Investment Advisor/Hedge Fund
11.85%
Venture Capital
8.63%
Hedge Fund
5.73%
Private Equity
4.92%
Individual Investor
2.32%
Research Firm
1.96%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.41%
Institutional Shareholding
Update time: Wed, Mar 5
Update time: Wed, Mar 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
216
105.29M
60.63%
-54.29M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
2022Q4
172
79.41M
72.57%
+27.33M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bain Capital Life Sciences Investors, LLC
16.92M
9.74%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
14.99M
8.63%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
10.26M
5.91%
-93.42K
-0.90%
Dec 31, 2024
The Vanguard Group, Inc.
8.20M
4.72%
-239.83K
-2.84%
Dec 31, 2024
Acorn Capital Advisors, LLC
7.31M
4.21%
--
--
Dec 31, 2024
OrbiMed Advisors, LLC
7.13M
4.11%
--
--
Dec 31, 2024
Kingdon Capital Management, L.L.C.
4.94M
2.84%
+298.32K
+6.43%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.50M
2.01%
+49.70K
+1.44%
Dec 31, 2024
AXA Investment Managers UK Ltd.
3.07M
1.77%
-4.80K
-0.16%
Dec 31, 2024
State Street Global Advisors (US)
3.06M
1.76%
+104.40K
+3.54%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Simplify Propel Opportunities ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data